Drugs / BI 3031185
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07656792 | Jul → Nov 2026 expected | — | Boehringer Ingelheim | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07211425 | Oct 2025 → Jan 2026 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT07001475 | Aug 2025 → Aug 2026 overdue | attention deficit-hyperactivity disorder, borderline personality disorder | Boehringer Ingelheim | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06916702 | Apr 2025 → Oct 2026 expected | — | Boehringer Ingelheim | Recruiting | No outcome recorded |
| Phase 1 | NCT06255340 | Mar → Aug 2024 | — | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI 3031185 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07211425 ↗ |
| Route | Oral | “BI 3031185 Administered as Tablet” NCT06255340 ↗ |